Companion Animal Diagnostics Market Forecasts to 2030 – Global Analysis By Product Type (Instruments, Reagents & Kits, Consumables, Software, and Other Product Types), Animal Type, Diagnostic Method, Application, End User and By Geography

According to Stratistics MRC, the Global Companion Animal Diagnostics Market is accounted for $5.92 billion in 2024 and is expected to reach $11.32 billion by 2030 growing at a CAGR of 11.4% during the forecast period. Companion animal diagnostics is the process of diagnosing illnesses and ailments in pets, including dogs, cats, and other animals, using a variety of instruments, examinations, and methods. Veterinary professionals use clinical chemistry, molecular diagnostics, immunodiagnostics, imaging technologies, and laboratory testing in this sector to assist identify diseases early, track the effectiveness of treatments. Better preventative care and treatment choices for companion animals are made possible by improvements in diagnostics, which increase the precision and effectiveness of ailment diagnosis.

According to the data published by the North American Pet Health Insurance Association Inc., in 2023, the total premium volume for pet insurance in the country was USD 3.2 billion. The total number of pets insured in the country at year-end 2022 was 4.8 million, a 22% increase since 2021.

Market Dynamics:

Driver:

Increase in animal healthcare spending

Veterinary services are in greater demand as a result of the sharp increase in pet ownership, particularly in developed nations. Owners are more inclined to make investments in their pets' health and wellbeing as they are increasingly seen as part of the family. Improvements in veterinary medicine and diagnostic technology, like imaging and molecular diagnostics, increase the efficacy of early disease identification and promote spending on preventative treatment. Pet owners' willingness to spend more money on medical care and diagnostic services for their animals is also encouraged by the growing prevalence of chronic diseases in pets and increased awareness of the advantages of routine checkups.

Restraint:

Limited insurance coverage

Financial limitations for diagnostic procedures can discourage many pet owners from seeking early diagnosis or treatment for their animals. This may result in the delayed identification of severe medical disorders, which could have a detrimental effect on the pet's health and ultimately raise treatment expenses. Additionally, lower-income households are disproportionately impacted by the lack of comprehensive insurance alternatives, which restricts their access to cutting-edge diagnostic equipment and care. This could restrict market growth and impede the development of more widely available veterinary diagnostics, leading to an under diagnosis of diseases, fewer veterinary visits, and ultimately worse health outcomes for pets.

Opportunity:

Expansion of veterinary clinics and hospitals

The demand for top-notch diagnostic equipment and services rises as more veterinary clinics are built and outfitted with cutting-edge diagnostic technologies. By providing a wider range of diagnostic tests, including imaging, molecular diagnostics, and clinical chemistry, these enlarged facilities can improve the quality of pet healthcare. Larger and more specialized veterinary clinics also serve the increasing number of pet owners who want prompt, thorough, and preventative care for their animals. The adoption of cutting-edge diagnostic services and products is fuelled by the rise of the veterinary industry and offers chances for diagnostic solution innovation.

Threat:

Shortage of trained professionals

The quality and accessibility of veterinary services are seriously hampered by the lack of qualified personnel in the companion animal diagnostics industry. It becomes more difficult to detect pet health issues accurately and promptly when there are insufficiently qualified veterinarians and laboratory professionals, which can result in misdiagnosis or delayed treatments. Because skilled personnel are needed to interpret results and operate complicated equipment, this shortage may also make it more difficult to use advanced diagnostic instruments effectively. Furthermore, areas with a shortage of trained personnel may see higher diagnostic service charges and longer wait times, which would lower the overall efficacy of companion animal healthcare and impede the uptake of state-of-the-art diagnostic tools.

Covid-19 Impact

The COVID-19 pandemic had a mixed impact on the companion animal diagnostics market. Initially, lockdowns and restrictions led to a decrease in veterinary visits and diagnostic procedures due to concerns about human health and limited access to clinics. However, as pet ownership surged during the pandemic, the demand for pet healthcare increased, fueling the need for diagnostic services. Additionally, the pandemic highlighted the importance of preventive care, leading to a long-term shift toward more routine diagnostic check-ups for pets.

The consumables segment is expected to be the largest during the forecast period

The consumables segment is expected to account for the largest market share during the forecast period, due to the necessity of ongoing pet health monitoring and the rise in standard diagnostic testing. For routine diagnostic procedures, consumables such reagents, test kits, and sample collection materials are necessary. The demand for dependable, disposable consumables increases as veterinary clinics and hospitals broaden their diagnostic capabilities, which fuels market expansion. Innovations in point-of-care diagnostics also increase the demand for consumables.

The veterinary clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the veterinary clinics segment is predicted to witness the highest growth rate. Clinics witness an increase in demand for diagnostic services as pet owners become more involved in the health of their animals and pet ownership rises. This makes sophisticated diagnostic equipment and tools necessary in these clinics. The market is growing because pet owners are encouraged to seek more thorough treatment, which frequently includes diagnostic testing, by the increase in pet insurance coverage.

Region with largest share:

During the forecast period, Asia Pacific region is expected to hold the largest market share, due to rising disposable incomes, and improving awareness of pet healthcare. With expanding veterinary infrastructure and greater access to advanced diagnostic tools, more pet owners are seeking regular health check-ups for their animals. This trend is driving demand for diagnostic services, fostering innovation, and encouraging market expansion, particularly in countries like China and India.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to high pet ownership and a strong focus on pet health and wellness. Pet owners are increasingly seeking advanced diagnostic solutions, driving demand for cutting-edge technologies like molecular diagnostics and imaging tools. This trend has led to the expansion of veterinary clinics and hospitals, encouraging growth in the market. Additionally, rising disposable incomes contribute to increase spending on pet healthcare and diagnostics.

Key players in the market

Some of the key players profiled in the Companion Animal Diagnostics Market include Idexx Laboratories, Inc., Thermo Fisher Scientific, Inc., Heska Corporation, Virbac, Elanco Animal Health, Randox Laboratories, Zoetis Inc., Boehringer Ingelheim, Medi-Lab, VCA Animal Hospitals, Neogen Corporation, Horizon Veterinary Diagnostics, BioNote, Inc., Reflxion, and Agrolabo S.P.A.

Key Developments:

In December 2024, Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the GibcoCTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8. These latest products expand on Thermo Fisher’s CTS Detachable Dynabeads platform, which represents a new generation of cell therapy isolation and/or activation products that prioritize cell quality while also creating greater workflow control.

In December 2024, IDEXX Laboratories, Inc. announced that the Company’s Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company’s common stock. Repurchases may be made at management’s discretion from time to time in the open market or in negotiated transactions.

Product Types Covered:
• Instruments
• Reagents & Kits
• Consumables
• Software
• Other Product Types

Animal Types Covered:
• Dogs
• Cats
• Horses
• Other Animal Types

Diagnostic Methods Covered:
• Hematology
• Molecular Diagnostics
• Immunodiagnostics
• Clinical Chemistry
• Fecal Testing
• Imaging
• Urinalysis
• Other Methods

Applications Covered:
• Bacteriology
• Virology
• Clinical Pathology
• Parasitology
• Other Applications

End Users Covered:
• Veterinary Clinics
• Veterinary Hospitals
• Point-of-care Testing
• Diagnostic Laboratories
• Research Institutes and Universities
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements